Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
16.15
-3.69 (-18.60%)
At close: May 8, 2026, 4:00 PM EDT
16.19
+0.04 (0.25%)
After-hours: May 8, 2026, 7:57 PM EDT
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|
| Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
|---|
Molecular Profiling Services Revenue | 863.44M | 766.72M | 349.12M | | | | | |
Molecular Profiling Services Revenue Growth | 12.62% | 119.62% | 25.24% | | | | | |
Pharma Research and Development Services Revenue | 43.85M | 45.31M | 63.15M | | | | | |
Pharma Research and Development Services Revenue Growth | -3.22% | -28.24% | 130.63% | | | | | |
| 907.29M | 812.03M | 412.26M | | | | | |
| 11.73% | 96.97% | 34.67% | | | | | |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|
| Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
|---|
| 896.80M | 801.39M | 401.84M | | | | | |
United States Revenue Growth | 11.91% | 99.43% | 36.95% | | | | | |
| 10.50M | 10.64M | 10.42M | | | | | |
International Revenue Growth | -1.35% | 2.07% | -18.05% | | | | | |
| 907.29M | 812.03M | 412.26M | | | | | |
| 11.73% | 96.97% | 34.67% | | | | | |
Key Performance Indicators
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|
| Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
|---|
Molecular Intelligence (MI) Profile - Clinical Case Volume | 173.86K | 170.30K | 146.60K | | | | | |
Molecular Intelligence (MI) Profile - Clinical Case Volume Growth | 2.09% | 16.17% | - | | | | | |
Caris Assure - Clinical Case Volume | 32.43K | 29.00K | 16.30K | | | | | |
Caris Assure - Clinical Case Volume Growth | 11.84% | 77.91% | - | | | | | |
Total Clinical Case Volume | 206.30K | 199.30K | 162.90K | | | | | |
Total Clinical Case Volume Growth | 3.51% | 22.35% | 26.47% | | | | | |
Molecular Intelligence (MI) Profile - Clinical Average Selling Price (ASP) | - | 4.03K | 2.20K | | | | | |
Molecular Intelligence (MI) Profile - Clinical Average Selling Price (ASP) Growth | - | 83.17% | - | | | | | |
Caris Assure - Clinical Average Selling Price (ASP) | - | 2.80K | 1.65K | | | | | |
Caris Assure - Clinical Average Selling Price (ASP) Growth | - | 69.29% | - | | | | | |
Updated May 8, 2026. Data Source:
Fiscal.ai.
